...
首页> 外文期刊>Current computer-aided drug design >Artificial Neural Network Analysis of Pharmacokinetic and Toxicity Properties of Lead Molecules for Dengue Fever, Tuberculosis and Malaria
【24h】

Artificial Neural Network Analysis of Pharmacokinetic and Toxicity Properties of Lead Molecules for Dengue Fever, Tuberculosis and Malaria

机译:人工神经网络分析铅分子对登革热,肺结核和疟疾的药代动力学和毒性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Poor pharmacokinetic and toxicity profiles are major reasons for the low rate of advancing lead drug candidates into efficacy studies. The In-silico prediction of primary pharmacokinetic and toxicity properties in the drug discovery and development process can be used as guidance in the design of candidates. In-silico parameters can also be used to choose suitable compounds for in-vivo testing thereby reducing the number of animals used in experiments. At the Novartis Institute for Tropical Diseases, a data set has been curated from in-house measurements in the disease areas of Dengue, Tuberculosis and Malaria. Volume of distribution, half-life, total in-vivo clearance, in-vitro human plasma protein binding and in-vivo oral bioavailability have been measured for molecules in the lead optimization stage in each of these three disease areas. Data for the inhibition of the hERG channel using the radio ligand binding dofetilide assay was determined for a set of 300 molecules in these therapeutic areas. Based on this data, Artificial Neural Networks were used to construct In-silico models for each of the properties listed above that can be used to prioritize candidates for lead optimization and to assist in selecting promising molecules for in-vivo pharmacokinetic studies.
机译:不良的药代动力学和毒性特征是导致领先候选药物进入疗效研究的比率较低的主要原因。药物发现和开发过程中主要药代动力学和毒性特性的计算机模拟预测可以用作候选药物设计的指导。硅内参数还可用于选择合适的化合物进行体内测试,从而减少实验中使用的动物数量。在诺华热带病研究所,已经从登革热,结核病和疟疾疾病地区的内部测量中收集了一个数据集。在这三个疾病领域的每个领域中,已针对领先优化阶段中的分子测量了分布体积,半衰期,总体内清除率,体外人血浆蛋白结合和体内口服生物利用度。对于这些治疗领域中的一组300个分子,确定了使用放射性配体结合多普利特测定法抑制hERG通道的数据。基于此数据,人工神经网络被用于针对上面列出的每个属性构建计算机模拟模型,这些模型可用于对潜在顾客进行铅优化的优先级排序,并协助选择有希望的分子进行体内药代动力学研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号